# Ornithine Transcarbamylase Deficiency
Who / What
**Ornithine transcarbamylase deficiency (OTC deficiency)** is a genetic disorder characterized by an enzyme defect in the urea cycle, specifically affecting **ornithine transcarbamylase**, which converts carbamoyl phosphate and ornithine into citrulline. This condition disrupts ammonia metabolism, leading to elevated blood ammonia levels and potential neurological complications.
---
Background & History
Ornithine transcarbamylase deficiency is recognized as the most common **urea cycle disorder** in humans. The genetic mutation underlying this condition was first identified through studies of metabolic disorders in the mid-20th century, though its precise mechanisms were refined later. Early research linked it to X-linked inheritance patterns, revealing that males are disproportionately affected due to their single X chromosome carrying the defective gene.
---
Why Notable
OTC deficiency holds significant clinical importance because it highlights critical vulnerabilities in ammonia detoxification, a process essential for brain function and overall health. Its prevalence as a genetic disorder underscores the need for early diagnosis and intervention, particularly in newborn screening programs. The condition also serves as a model for understanding inherited metabolic diseases, influencing advancements in genetic counseling, enzyme replacement therapies, and supportive care strategies.
---
In the News
Currently, OTC deficiency remains a topic of ongoing research, particularly regarding its management in neonatal populations and potential therapeutic interventions. Recent developments emphasize the importance of prenatal diagnosis and targeted dietary or medical treatments to mitigate symptoms. The condition continues to attract attention due to its implications for genetic screening programs and broader public health strategies aimed at metabolic disease prevention.
---
Key Facts
---
